Details of the Drug

General Information of Drug (ID: DMF6Y0L)

Drug Name
Polatuzumab vedotin
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Approved [1]
Follicular lymphoma 2A80 Phase 2 [2]
Haematological malignancy 2B33.Y Phase 2 [3]
Drug Type
Antibody
ADMET Property
Clearance
The clearance of drug is 0.9 L/day []
Half-life
The concentration or amount of drug in body reduced by one-half in 12 days [4]
Metabolism
The drug is metabolized via the cytochrome P450 3A4 []
Vd
The volume of distribution (Vd) of drug is 3.15 L []
Cross-matching ID
DrugBank ID
DB12240
TTD ID
D05QOL
INTEDE ID
DR1311
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell-specific glycoprotein B29 (CD79B) TTBN5I7 CD79B_HUMAN Not Available [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Polatuzumab vedotin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Polatuzumab vedotin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [6]
Troleandomycin DMUZNIG Major Decreased metabolism of Polatuzumab vedotin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [7]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Polatuzumab vedotin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [8]
Tazemetostat DMWP1BH Moderate Increased metabolism of Polatuzumab vedotin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [9]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Polatuzumab vedotin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [7]
Selpercatinib DMZR15V Moderate Decreased metabolism of Polatuzumab vedotin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [7]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Polatuzumab vedotin and Siponimod. Multiple sclerosis [8A40] [6]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Polatuzumab vedotin and Ozanimod. Multiple sclerosis [8A40] [10]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Polatuzumab vedotin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [7]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Polatuzumab vedotin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [7]
Lefamulin DME6G97 Moderate Decreased metabolism of Polatuzumab vedotin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [11]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Polatuzumab vedotin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [7]
Larotrectinib DM26CQR Moderate Decreased metabolism of Polatuzumab vedotin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [7]
⏷ Show the Full List of 13 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA label of Polatuzumab vedotin-piiq. The 2020 official website of the U.S. Food and Drug Administration.
6 Cerner Multum, Inc. "Australian Product Information.".
7 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
8 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
9 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
10 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.